[Infections in bone marrow transplantation].
Villasís-Keever
Angelina
A
Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, DF. avkeever@prodigy.net.mx
Mosqueda
Juan Luis
JL
D000257:Adenoviridae Infections / Q000188:drug therapy / Q000453:epidemiology; D000935:Antifungal Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D003587:Cytomegalovirus / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000453:epidemiology / Q000635:transmission; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy / Q000453:epidemiology / Q000635:transmission; D004854:Herpesvirus 4, Human / Q000502:physiology; D006801:Humans; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007239:Infections / Q000453:epidemiology* / Q000209:etiology / Q000635:transmission; D009181:Mycoses / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D011183:Postoperative Complications / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000821:virology; D011184:Postoperative Period; D012307:Risk Factors; D019172:Transplantation Conditioning / Q000009:adverse effects; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous / Q000009:adverse effects; D014775:Virus Activation
D000935:Antifungal Agents; D000998:Antiviral Agents